These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23541592)

  • 1. Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samples.
    Stanoszek LM; Crawford EL; Blomquist TM; Warns JA; Willey PF; Willey JC
    J Mol Diagn; 2013 May; 15(3):391-400. PubMed ID: 23541592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion, correction, and International Scale standardization: results From a Multicenter External Quality Assessment Study for BCR-ABL1 testing.
    Griffiths M; Patton SJ; Grossi A; Clark J; Paz MF; Labourier E;
    Arch Pathol Lab Med; 2015 Apr; 139(4):522-9. PubMed ID: 25061833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.
    Ross DM; Watkins DB; Hughes TP; Branford S
    Clin Chem; 2008 Sep; 54(9):1568-71. PubMed ID: 18641042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
    Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
    Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a novel multiplex RT-qPCR assay for the quantification of leukemia-associated BCR-ABL1 translocation.
    Kottwitz D; El Hadi H; El Amrani M; Cabezas S; Dehbi H; Nadifi S; Quessar A; Colomer D; Moumen A; Sefrioui EL
    Int J Hematol; 2015 Sep; 102(3):335-41. PubMed ID: 26243622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes.
    Stuckey R; Casado LF; Colomer D; Gómez-Casares MT; Casas L; García-Gutierrez V; Sastre JL; Ramírez-Payer Á; Vall-Llovera F; Goñi MÁ; Xicoy B; Godoy AC; Núñez J; Mora I; Vallansot R; López-Lorenzo JL; Palomera L; Conesa V; Noya MS; Sánchez-Guijo F; Peña A; Bautista G; Steegmann JL
    J Mol Diagn; 2020 Oct; 22(10):1217-1224. PubMed ID: 32688056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programme for Harmonization to the International Scale in Latin America for BCR-ABL1 quantification in CML patients: findings and recommendations.
    Ruiz MS; Sánchez MB; Vera Contreras YM; Agrielo E; Alonso M; Altuna ME; Anchordoqui MS; Asinari M; Bonetto ME; Camargo M; Giere I; González J; Granda Alacote AC; Guerra J; Gutiérrez M; Maldonado C; Makiya R; Manrique G; Monaco ME; Rozo JC; Santamaría C; Seravalle A; Zea O; Zubillaga MN; Mordoh J; Larripa I; Bianchini M
    Clin Chem Lab Med; 2020 Nov; 58(12):2025-2035. PubMed ID: 32374276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
    Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
    Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.
    Spiess B; Rinaldetti S; Naumann N; Galuschek N; Kossak-Roth U; Wuchter P; Tarnopolscaia I; Rose D; Voskanyan A; Fabarius A; Hofmann WK; Saußele S; Seifarth W
    PLoS One; 2019; 14(3):e0214305. PubMed ID: 30897165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study.
    Scott S; Cartwright A; Francis S; Whitby L; Sanzone AP; Mulder A; Galimberti S; Dulucq S; Mauté C; Lauricella C; Salmon M; Rose S; Willoughby J; Boeckx N; Pallisgaard N; Maier J; Leibundgut EO; Zizkova H; Ling Goh L; Duong C; Tang WF; Ma E; Shivakumar Y; Beppu L; Bhagavatula P; Chantry A
    Br J Haematol; 2021 Jul; 194(1):53-60. PubMed ID: 34114218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
    Ma W; Tseng R; Gorre M; Jilani I; Keating M; Kantarjian H; Cortes J; O'Brien S; Giles F; Albitar M
    Haematologica; 2007 Feb; 92(2):170-5. PubMed ID: 17296565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.
    Schäfer V; White HE; Gerrard G; Möbius S; Saussele S; Franke GN; Mahon FX; Talmaci R; Colomer D; Soverini S; Machova Polakova K; Cross NCP; Hochhaus A; Ernst T
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3081-3089. PubMed ID: 33677711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External quality assessment of p210 BCR-ABL1 transcript quantification by RT-qPCR: Findings and recommendations.
    Fu Y; Zhang R; Wu Q; Zhang J; Bao L; Li J
    Int J Lab Hematol; 2019 Feb; 41(1):46-54. PubMed ID: 30203581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-time quantification assay to monitor BCR-ABL1 transcripts in chronic myeloid leukemia.
    Foskett P; Gerrard G; Foroni L
    Methods Mol Biol; 2014; 1160():115-24. PubMed ID: 24740226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.
    Brown JT; Beldorth IJ; Laosinchai-Wolf W; Fahey ME; Jefferson KL; Ruskin AK; Roth JJ; Cai L; Watt CD; Press RD; Yang F; Hedges JB; Andruss BF
    J Mol Diagn; 2019 Jul; 21(4):718-733. PubMed ID: 31026597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation.
    Schumacher JA; Szankasi P; Bahler DW; Ho AK; Kelley TW
    J Clin Pathol; 2011 Jul; 64(7):618-25. PubMed ID: 21486895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost?
    Cayuela JM; Macintyre E; Darlington M; Abdelali RB; Fund X; Villarese P; Tulliez M; Raffoux E; Sigaux F; Réa D; Seror V
    Haematologica; 2011 May; 96(5):664-71. PubMed ID: 21330326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Guidelines for molecular monitoring of BCR-ABL1 in chronic myeloid leukemia patients by RT-qPCR].
    Larripa I; Ruiz MS; Gutiérrez M; Bianchini M
    Medicina (B Aires); 2017; 77(1):61-72. PubMed ID: 28140313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the challenge in measuring and standardizing BCR-ABL1.
    Yu S; Cui M; He X; Jing R; Wang H
    Clin Chem Lab Med; 2017 Aug; 55(10):1465-1473. PubMed ID: 28222016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts.
    Wang YL; Lee JW; Cesarman E; Jin DK; Csernus B
    J Mol Diagn; 2006 May; 8(2):231-9. PubMed ID: 16645210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.